Drugs / NKX101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04623944 | Sep 2020 → Oct 2024 overdue | acute myeloid leukemia, myelodysplastic syndrome | Nkarta, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-12-09 | Nkarta, Inc. | Results Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition nkartatx.com ↗
In the follow up presented today, three of those four patients remained in CR/CRi at 4 months from treatment with NKX101. |
| 2023-06-27 | Nkarta, Inc. | Results Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia nkartatx.com ↗ |
| 2023-04-17 | Nkarta, Inc. | Results Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting nkartatx.com ↗
Specifically, we’ve shown that NKX101, our clinical candidate engineered with an NKG2D-based CAR, can be combined with cetuximab to enhance activity towards EGFR-expressing tumor cells. |
| 2022-04-25 | Nkarta, Inc. | Results Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs nkartatx.com ↗
3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative |
| 2021-12-16 | Nkarta, Inc. | Regulatory Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML nkartatx.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04623944 ↗ |
| Modality | Cell therapy | “NKX101 - CAR NK cell therapy” NCT04623944 ↗ |
| Route | Intravenous | “Intravenous Allogeneic CAR NK Cells” NCT04623944 ↗ |